Want to see FR:ALNOV full AI Analyst Report?
ALNOV Stock Chart & Stats
€0.49
<€0.01(0.90%)
At close: 4:00 PM EDT
€0.49
<€0.01(0.90%)
Day’s Range― - ―
52-Week Range€0.29 - €1.04
Previous CloseN/A
Volume30.11K
Average Volume (3M)285.83K
Market Cap
€33.50M
Enterprise Value€29.84M
Total Cash (Recent Filing)€8.88M
Total Debt (Recent Filing)€10.19M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Apr 29, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding72,588,090
10 Day Avg. Volume339,576
30 Day Avg. Volume285,832
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.18
Price to Sales (P/S)1.35
P/FCF Ratio-3.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€30.37M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthRepeated revenue growth across three consecutive half-years indicates improving commercial traction rather than a single temporary uplift. Continued expansion supports operating leverage, strengthens customer adoption, and provides a broader base from which Novacyt can scale its diagnostics portfolio.
Portfolio And Market ExpansionRegulatory approval for a clinically relevant assay expands the addressable market, while the Australian acquisition and Illumina collaboration broaden distribution and strategic reach. Together, these initiatives can create more durable revenue opportunities across products and geographies.
Cost-reduction ProgramThe restructuring has already identified substantial recurring savings through labor and nonlabor actions. If implemented as planned, the lower cost base should improve operating leverage and materially reduce future cash burn, helping revenue growth translate more effectively into earnings.
Bears Say
Persistent UnprofitabilityPersistent operating and EBITDA losses show that the current revenue base still does not cover the company’s cost structure. Until profitability is achieved, Novacyt has less internally generated funding for product development, commercial expansion, and resilience against execution setbacks.
Ongoing Cash ConsumptionSustained negative cash flow increases dependence on the existing cash balance and future financing or operational improvement. Continued consumption could constrain investment and reduce financial flexibility, particularly if restructuring benefits arrive later than expected or losses persist.
Margin Pressure And RUO WeaknessLower gross margin and declining high-margin RUO revenue weaken the quality of current growth. Although management expects margin recovery, a less favorable mix can delay breakeven, reduce operating leverage, and make the company more reliant on successful commercialization and cost control.
Novacyt News
ALNOV FAQ
What was Novacyt’s price range in the past 12 months?
Novacyt lowest stock price was €0.29 and its highest was €1.04 in the past 12 months.
What is Novacyt’s market cap?
Novacyt’s market cap is €33.50M.
When is Novacyt’s upcoming earnings report date?
Novacyt’s upcoming earnings report date is Apr 29, 2027 which is in 197 days.
How were Novacyt’s earnings last quarter?
Novacyt released its earnings results on Sep 30, 2026. The company reported -€0.093 earnings per share for the quarter.
Is Novacyt overvalued?
According to Wall Street analysts Novacyt’s price is currently Overvalued.
Does Novacyt pay dividends?
Novacyt does not currently pay dividends.
What is Novacyt’s EPS estimate?
Novacyt’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novacyt have?
Novacyt has 72,588,090 shares outstanding.
What happened to Novacyt’s price movement after its last earnings report?
Novacyt reported an EPS of -€0.093 in its last earnings report. Following the earnings report the stock price went down -2.174%.
Which hedge fund is a major shareholder of Novacyt?
Currently, no hedge funds are holding shares in FR:ALNOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novacyt
Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A. and its subsidiaries are actively involved in the full lifecycle of diagnostic products, encompassing development, manufacturing, custom design, and global commercialization. These vital diagnostic tools are employed in the detection of both cancer and a variety of infectious diseases. The company boasts an extensive international reach, serving markets throughout the United Kingdom, wider Europe, the United States, the Asia Pacific region, the Middle East, and Africa. Novacyt's operations are structured around three core segments. Primer Design specializes in the creation, production, and sale of molecular real-time qPCR testing devices and reagents, primarily for infectious disease diagnostics. Lab21 Products focuses on developing, manufacturing, and distributing a diverse portfolio of protein-based in-vitro diagnostic (IVD) products, also targeting infectious diseases. The IT-IS International segment is dedicated to engineering and fabricating PCR instruments used in the life sciences and food testing industries. The company's clientele principally includes hospitals and various corporate organizations.
ALNOV Company Deck
ALNOV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive. Management highlighted 18% year-on-year revenue growth, three consecutive half-years of growth, broad geographic and product expansion, the Southern Cross contribution, the DPYD launch, the five-year Illumina agreement and substantial operating-cost reductions. The principal negatives were the decline in gross margin to 56%, lower RUO sales, continued EBITDA losses, cash consumption and an incomplete restructuring program. Management characterized the cost actions as on plan and said cash burn should materially decline after restructuring.View all FR:ALNOV earnings summariesTechnical Analysis
MAUNA KEA TECHNOLOGIES
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―